Katherine Mondada, PA
Physician Assistant · Nampa, IDNPI 1598231623
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,183 of the $6,053 with a category attached, or 85.6%. It is spread thinly across 37 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,866, 2.1 times the $906 reported in 2021. Among physician assistant clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $51.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$654
- AstraZeneca$440
- AbbVie$432
- Gilead$432
- Tempus AI, Inc$421
- E.r. Squibb & Sons, L.L.C.$311
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,18386%
- Education$87014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 12 | $654 |
| AstraZeneca(2 entities) | 9 | $440 |
| AbbVie | 6 | $432 |
| Gilead(2 entities) | 7 | $432 |
| Tempus AI, Inc | 5 | $421 |
| E.r. Squibb & Sons, L.L.C. | 5 | $311 |
| Amgen | 6 | $301 |
| Daiichi Sankyo Inc. | 6 | $298 |
| Jazz Pharmaceuticals Inc. | 2 | $250 |
| Seagen Inc. | 3 | $206 |
| Astellas Pharma US Inc | 3 | $188 |
| Exelixis Inc. | 3 | $183 |
| Sumitomo Pharma America, Inc. | 2 | $175 |
| Foundation Medicine, Inc. | 2 | $173 |
| Incyte Corporation | 3 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $145 |
| EMD Serono, Inc. | 3 | $137 |
| Bayer | 2 | $135 |
| Novartis | 6 | $128 |
| Genentech USA, Inc. | 7 | $127 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Beigene USA, Inc. | 1 | $125 |
| AVEO Pharmaceuticals, Inc. | 1 | $85 |
| Bristol Myers Squibb | 3 | $57 |
| Genentech, Inc. | 1 | $53 |
| Boehringer Ingelheim | 2 | $41 |
| Merck | 2 | $40 |
| Kyowa Kirin, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $32 |
| Stemline Therapeutics Inc. | 1 | $28 |
| Sobi, Inc | 1 | $24 |
| Eisai Inc. | 1 | $22 |
| Immunogen, Inc. | 1 | $18 |
| GSK | 1 | $17 |
| Morphosys, US Inc. | 1 | $17 |
| Clovis Oncology, Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,053 in reported general payments places this provider in the 95th percentile of 1,027 physician assistant providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 11 | $123,639 |
| EliquisApixaban | 20 | $12,783 |
| XareltoRivaroxaban | 11 | $6,364 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $724 |
| Hydroxyurea | 26 | $542 |
| Letrozole | 17 | $436 |
| Tamoxifen Citrate | 14 | $433 |
| Anastrozole | 26 | $412 |
| Prochlorperazine Maleate | 19 | $411 |
| Ondansetron Hcl | 20 | $389 |
| Dexamethasone | 13 | $279 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $204 |
| Prednisone | 21 | $129 |
| Potassium Chloride | 14 | $116 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 12 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $432 | $123,63911 claims |
| Johnson & JohnsonXarelto | $654 | $6,36411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,027 physician assistant providers in Idaho.
Other physician assistant in Nampa
- James WalkerNampa$21K
- Seth PermannNampa$9K
- Amanda TurnerNampa$7K
- Thea HeatonNampa$6K
- Emily StegeNampa$6K
- Benjamin KernsBoise$100K
- Brian BizikTwin Falls$81K
- Autumn HeumanBoise$28K
- Melissa McClenahanMeridian$19K
- Kimberly PortchCoeur D Alene$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.